September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Expression of the biomarkers K19, SOX2 und p63 in conjunctival squamous cell carcinoma
Author Affiliations & Notes
  • Henning Thomasen
    Ophthalmology, University of Duisburg-Essen, Essen, Germany
  • Dirk Dekowski
    Ophthalmology, University of Duisburg-Essen, Essen, Germany
  • Sarah Synoracki
    Pathology, University Hospital Essen, Essen, Germany
  • Klaus-Peter Steuhl
    Ophthalmology, University of Duisburg-Essen, Essen, Germany
  • Daniel Meller
    Ophthalmology, University Hospital Jena, Jena, Germany
  • Footnotes
    Commercial Relationships   Henning Thomasen, None; Dirk Dekowski, None; Sarah Synoracki, None; Klaus-Peter Steuhl, None; Daniel Meller, None
  • Footnotes
    Support  Dr. Werner Jackstädt Stiftung
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2410. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Henning Thomasen, Dirk Dekowski, Sarah Synoracki, Klaus-Peter Steuhl, Daniel Meller; Expression of the biomarkers K19, SOX2 und p63 in conjunctival squamous cell carcinoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2410.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The biomarkers p63 and SOX are expressed in squamous cell carcinoma of different localization, where their presence seems to be linked to tumor progression. The expression of these markers in conjunctival SCC (CSCCs) has not been studied so far. This study examines the expression of p63, SOX2 and the conjunctival cytokeratin K19 in CSCCs in relation to clinical data of the patients in order to evaluate the prognostic value of the markers for CSCCs.

Methods : In total 65 paraffin-embedded samples of CSCCs, confirmed by pathological examination, were analyzed. Samples were stained immunhistologically for p63, SOX2 and K19. The intensity of the staining signal and the percentage of positive cells were determined by a pathologist afterwards the immunoreactive score (IRS) of each marker was calculated for every sample. The IRS was classified as either weak, moderate or strong. It was aligned to the severity of the malignancy.

Results : 24% of all samples showed a positive staining for K19, 49% were positive for SOX2 and 94% were positive for p63 with IRS scores including all degrees. In 14 patients orbital exenteration was required. In 8 eyes of them the IRS score revealed a simultaneous expression of SOX2 and p63. In two notable cases of the exenterations, one where infiltration of the globe and metastasis of the lymph nodes and one where aggressive relapse and bulbar infiltration occurred, tumor samples displayed a strong simultaneous IRS score for SOX2 and p63. K19 was detected in 6 enucleated eyes. The remaining 51 eyes could be saved. They displayed expression of the three markers of various intensities. A co-expression of SOX2 and p63 in the sustained eyes occurred in 16 eyes. There was no statistically significant connection between the IRS of the different markers, neither the of a single marker nor of a combination of markers, and the clinical outcome.

Conclusions : The high overall number of K19 negative samples might be associated with the loss of regular differentiation status in CSSCs leading to an overall loss of epithelial differentiation markers. The prominence of p63 in the samples is a regular sign of SCC progression. SOX2 expression is less frequent in CSSCs than p63. Although a simultaneous expression of p63 and SOX2 was noticed more in prominent CSSCs compared to less aggressive tumors there is no significant correlation between the IRS of the markers and clinical tumor development .

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×